buyWeak cluster of 2
Niklason Laura E bought $7,979 of HUMA
President, CEO and Director at Humacyte, Inc.. 1,797 shares at an average of $4.44, traded Nov 19, 2024, filed Nov 21, 2024.
Conviction score
28Value
$7,979
1,797 shares
Holdings after
243,851
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001818382-24-000214, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | POpen-market purchase Common Stock | +1,797 | $4.44 | $7,979 | 243,851 | Nov 21, 2024 |
Related signals
Other insiders at Humacyte, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 21Weak | buy | HUMA Humacyte, Inc. | Constantino Michael T. director | $20k | 4,600 | |
| 18Weak | buy 2 | HUMA Humacyte, Inc. | Dougan Brady W director | $7,979 | 1,797 | |
| 58Moderate | sell 2 | HUMA Humacyte, Inc. | Dougan Brady W director | $6.6M | 1,500,000 | |
| 68Notable | sell 2 | HUMA Humacyte, Inc. | Niklason Laura E President, CEO and Director | $6.6M | 1,500,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.